Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.

O'Keefe DS, Bacich DJ, Huang SS, Heston WDW.

J Nucl Med. 2018 Jul;59(7):1007-1013. doi: 10.2967/jnumed.117.203877. Epub 2018 Apr 19. Review.

2.

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?

Huang SS, Heston WDW.

Theranostics. 2017 Apr 1;7(7):1940-1941. doi: 10.7150/thno.20284. eCollection 2017.

3.

Selenoprotein P neutralizes lipopolysaccharide and participates in hepatic cell endoplasmic reticulum stress response.

Zhao Y, Banerjee S, Huang P, Wang X, Gladson CL, Heston WD, Foster CB.

FEBS Lett. 2016 Dec;590(24):4519-4530. doi: 10.1002/1873-3468.12494. Epub 2016 Nov 28.

4.

Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency.

Fuchs AV, Tse BW, Pearce AK, Yeh MC, Fletcher NL, Huang SS, Heston WD, Whittaker AK, Russell PJ, Thurecht KJ.

Biomacromolecules. 2015 Oct 12;16(10):3235-47. doi: 10.1021/acs.biomac.5b00913. Epub 2015 Sep 3.

PMID:
26335533
5.

The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.

Chatterjee P, Choudhary GS, Alswillah T, Xiong X, Heston WD, Magi-Galluzzi C, Zhang J, Klein EA, Almasan A.

Mol Cancer Ther. 2015 Aug;14(8):1896-906. doi: 10.1158/1535-7163.MCT-14-0865. Epub 2015 May 29.

6.

CD117⁺ cells in the circulation are predictive of advanced prostate cancer.

Kerr BA, Miocinovic R, Smith AK, West XZ, Watts KE, Alzayed AW, Klink JC, Mir MC, Sturey T, Hansel DE, Heston WD, Stephenson AJ, Klein EA, Byzova TV.

Oncotarget. 2015 Jan 30;6(3):1889-97.

7.

Development of targeted near-infrared imaging agents for prostate cancer.

Wang X, Huang SS, Heston WD, Guo H, Wang BC, Basilion JP.

Mol Cancer Ther. 2014 Nov;13(11):2595-606. doi: 10.1158/1535-7163.MCT-14-0422. Epub 2014 Sep 19.

8.

Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin).

Singh K, Sharma A, Mir MC, Drazba JA, Heston WD, Magi-Galluzzi C, Hansel D, Rubin BP, Klein EA, Almasan A.

Mol Cancer. 2014 Mar 23;13:70. doi: 10.1186/1476-4598-13-70.

9.

Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.

Huang SS, Wang X, Zhang Y, Doke A, DiFilippo FP, Heston WD.

Prostate. 2014 May;74(7):702-13. doi: 10.1002/pros.22789. Epub 2014 Feb 24.

PMID:
24615708
10.

PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.

Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, Klein EA, Almasan A.

PLoS One. 2013;8(4):e60408. doi: 10.1371/journal.pone.0060408. Epub 2013 Apr 2.

11.

Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study.

Laydner H, Huang SS, Heston WD, Autorino R, Wang X, Harsch KM, Magi-Galluzzi C, Isac W, Khanna R, Hu B, Escobar P, Chalikonda S, Rao PK, Haber GP, Kaouk JH, Stein RJ.

Urology. 2013 Feb;81(2):451-6. doi: 10.1016/j.urology.2012.02.075.

PMID:
23374828
12.

NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.

Janczura KJ, Olszewski RT, Bzdega T, Bacich DJ, Heston WD, Neale JH.

Eur J Pharmacol. 2013 Feb 15;701(1-3):27-32. doi: 10.1016/j.ejphar.2012.11.027. Epub 2012 Nov 29.

13.

Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.

Chan ES, Patel AR, Hansel DE, Larchian WA, Heston WD.

Urology. 2012 Sep;80(3):736.e1-5. doi: 10.1016/j.urology.2012.04.038. Epub 2012 Jun 5.

PMID:
22676953
14.

Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.

Wang X, Tian H, Lee Z, Heston WD.

Nucleosides Nucleotides Nucleic Acids. 2012 May;31(5):432-44. doi: 10.1080/15257770.2012.671988.

PMID:
22497258
15.

In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.

Wang X, Ma D, Olson WC, Heston WD.

Mol Cancer Ther. 2011 Sep;10(9):1728-39. doi: 10.1158/1535-7163.MCT-11-0191. Epub 2011 Jul 12.

16.

Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, Kobayashi H.

Bioconjug Chem. 2011 Aug 17;22(8):1700-5. doi: 10.1021/bc2002715. Epub 2011 Jul 27.

17.

Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.

Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WD.

PLoS One. 2011;6(6):e21319. doi: 10.1371/journal.pone.0021319. Epub 2011 Jun 24.

18.

Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.

Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH, Heston WD, Eng C.

Oncogene. 2011 Oct 20;30(42):4327-38. doi: 10.1038/onc.2011.144. Epub 2011 May 2.

PMID:
21532617
19.

In vivo targeted contrast enhanced micro-ultrasound to measure intratumor perfusion and vascular endothelial growth factor receptor 2 expression in a mouse orthotopic bladder cancer model.

Chan ES, Patel AR, Larchian WA, Heston WD.

J Urol. 2011 Jun;185(6):2359-65. doi: 10.1016/j.juro.2011.02.047. Epub 2011 Apr 21.

PMID:
21511281
20.

Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.

Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C.

Hum Mol Genet. 2010 Nov 15;19(22):4319-29. doi: 10.1093/hmg/ddq354. Epub 2010 Aug 20.

21.

Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model.

Chan ES, Patel AR, Smith AK, Klein JB, Thomas AA, Heston WD, Larchian WA.

J Urol. 2009 Dec;182(6):2926-31. doi: 10.1016/j.juro.2009.08.020. Epub 2009 Oct 20.

PMID:
19846165
22.

Transabdominal micro-ultrasound imaging of bladder cancer in a mouse model: a validation study.

Patel AR, Chan ES, Hansel DE, Powell CT, Heston WD, Larchian WA.

Urology. 2010 Apr;75(4):799-804. doi: 10.1016/j.urology.2009.06.047. Epub 2009 Sep 20.

PMID:
19773032
23.

Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.

Yao V, Parwani A, Maier C, Heston WD, Bacich DJ.

Cancer Res. 2008 Nov 1;68(21):9070-7. doi: 10.1158/0008-5472.CAN-08-2328.

24.

Clinical trials of cancer therapies targeting prostate-specific membrane antigen.

Olson WC, Heston WD, Rajasekaran AK.

Rev Recent Clin Trials. 2007 Sep;2(3):182-90. Review.

PMID:
18474004
25.

2-5A ligands--a new concept for the treatment of prostate cancer.

Cramer H, Okicki JR, Rho T, Wang X, Silverman RH, Heston WD.

Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1471-7.

PMID:
18066809
26.

Targeted treatment of prostate cancer.

Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, Heston WD.

J Cell Biochem. 2007 Oct 15;102(3):571-9. Review.

PMID:
17685433
27.

A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.

Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC.

Clin Cancer Res. 2007 Jul 1;13(13):3999-4008.

28.

Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy.

Jayaprakash S, Wang X, Heston WD, Kozikowski AP.

ChemMedChem. 2006 Mar;1(3):299-302. No abstract available.

PMID:
16892363
29.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M.

Cancer Res. 2005 Oct 1;65(19):9080-8.

30.

Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.

Bacich DJ, Wozniak KM, Lu XC, O'Keefe DS, Callizot N, Heston WD, Slusher BS.

J Neurochem. 2005 Oct;95(2):314-23.

31.

Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography.

Guilarte TR, McGlothan JL, Foss CA, Zhou J, Heston WD, Kozikowski AP, Pomper MG.

Neurosci Lett. 2005 Oct 28;387(3):141-4.

PMID:
16006038
32.

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.

Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG.

Clin Cancer Res. 2005 Jun 1;11(11):4022-8.

33.

Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.

Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, Heston WD, Houghton AN, Scher HI.

Int J Cancer. 2005 Sep 1;116(3):415-21.

34.

Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.

Ghosh A, Wang X, Klein E, Heston WD.

Cancer Res. 2005 Feb 1;65(3):727-31.

35.

Clearing up the confusion over the glutamate carboxypeptidase II gene.

O'Keefe DS, Heston WD.

Am J Med Genet A. 2004 Oct 15;130A(3):327; author reply 329-30. No abstract available.

PMID:
15368483
36.

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Ghosh A, Heston WD.

J Cell Biochem. 2004 Feb 15;91(3):528-39. Review.

PMID:
14755683
37.
38.

The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.

Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12590-5.

39.
40.

The clinical role of prostate-specific membrane antigen (PSMA).

Chang SS, Heston WD.

Urol Oncol. 2002 Jan-Feb;7(1):7-12.

PMID:
12474535
41.

Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate.

Bacich DJ, Ramadan E, O'Keefe DS, Bukhari N, Wegorzewska I, Ojeifo O, Olszewski R, Wrenn CC, Bzdega T, Wroblewska B, Heston WD, Neale JH.

J Neurochem. 2002 Oct;83(1):20-9.

42.

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.

Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, Fong Y.

Prostate. 2002 Oct 1;53(2):95-100.

PMID:
12242723
44.

A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?

Tasch J, Gong M, Sadelain M, Heston WD.

Crit Rev Immunol. 2001;21(1-3):249-61. Review.

PMID:
11642607
45.
46.

Overview consensus statement.

Carroll PR, Fair WR, Grossfeld GD, Heston WD, Lieberman R, Malkowicz SB, Stricker HJ, Sylvester J, Peehl DM, Meyer F, Hart C.

Urology. 2001 Aug;58(2 Suppl 1):1-4. No abstract available.

PMID:
11502434
47.
48.

A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1.

Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O'Keefe DS, Russell PJ, Heston WD, Molloy PL.

Genomics. 2001 May 1;73(3):243-54.

PMID:
11350116
49.

Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model.

Cozzi PJ, Malhotra S, McAuliffe P, Kooby DA, Federoff HJ, Huryk B, Johnson P, Scardino PT, Heston WD, Fong Y.

FASEB J. 2001 May;15(7):1306-8. No abstract available.

PMID:
11344122
50.

Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.

Chang SS, Reuter VE, Heston WD, Gaudin PB.

Urology. 2001 Apr;57(4):801-5.

PMID:
11306418

Supplemental Content

Loading ...
Support Center